NewSquare Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

NewSquare Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-44	Closed	-$2.42K	–	316
2025 Q2	$2.42K	Buy	44 +17	+63%	+$1K	﹤0.01%	932
2025 Q1	$1.91K	Buy	27 +16	+145%	+$1.08K	﹤0.01%	851
2024 Q4	$723	Buy	+11	New	+$737	﹤0.01%	681
2023 Q3	–	Sell	-8	Closed	-$693	–	636
2023 Q2	$693	Hold	8	–	–	﹤0.01%	650
2023 Q1	$778	Hold	8	–	–	﹤0.01%	678
2022 Q4	$828	Buy	+8	New	+$751	﹤0.01%	600

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

NewSquare Capital's BMRN Position: Q3 2025 in Review

NewSquare Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 44 shares — an estimated $2.42K sold.

NewSquare Capital first reported a position in BMRN in Q4 2022 and held it in 6 quarters. The position peaked at $2.42K in Q2 2025. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

NewSquare Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
NewSquare Capital sold 44 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $2.42K.
NewSquare Capital first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 6 quarters.
NewSquare Capital's BioMarin Pharmaceuticals position peaked at $2.42K in Q2 2025.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on NewSquare Capital's 13F filing for Q3 2025, filed 12 Nov 2025.